Online inquiry

IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2902MR)

This product GTTS-WQ2902MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL17RA gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001289905.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 23765
UniProt ID Q96F46
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2902MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6500MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CX-072
GTTS-WQ4910MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ13951MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-2810
GTTS-WQ13371MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ13508MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PRX002
GTTS-WQ1145MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABP 215
GTTS-WQ4519MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ14787MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SGN-40
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW